82 related articles for article (PubMed ID: 2274926)
1. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis.
Páramo JA; Pérez JL; Serrano M; Rocha E
Thromb Haemost; 1990 Aug; 64(1):3-6. PubMed ID: 2274926
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
3. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis.
Jessen KM; Lindboe SB; Petersen AL; Eugen-Olsen J; Benfield T
BMC Infect Dis; 2007 Sep; 7():108. PubMed ID: 17877801
[TBL] [Abstract][Full Text] [Related]
4. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
5. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
6. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis.
Kamper EF; Kopeikina LT; Trontzas P; Potamianou A; Tsiroglou E; Stavridis JC
J Rheumatol; 2000 Nov; 27(11):2545-50. PubMed ID: 11093432
[TBL] [Abstract][Full Text] [Related]
7. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
Cucuianu M; Knauer O; Roman S
Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
[TBL] [Abstract][Full Text] [Related]
8. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
He G; Andersen O; Haugaard SB; Lihn AS; Pedersen SB; Madsbad S; Richelsen B
Eur J Clin Invest; 2005 Sep; 35(9):583-90. PubMed ID: 16128865
[TBL] [Abstract][Full Text] [Related]
10. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
Orbe J; Chordá C; Montes R; Páramo JA
Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
[TBL] [Abstract][Full Text] [Related]
11. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Mesters RM; Flörke N; Ostermann H; Kienast J
Thromb Haemost; 1996 Jun; 75(6):902-7. PubMed ID: 8822584
[TBL] [Abstract][Full Text] [Related]
12. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
13. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor (PAI) in obese men and obese women.
Cucuianu M; Lanczek M; Roman S
Rom J Intern Med; 1993; 31(3):183-92. PubMed ID: 8130756
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Hamaguchi E; Takamura T; Shimizu A; Nagai Y
J Pharmacol Exp Ther; 2003 Dec; 307(3):987-94. PubMed ID: 14534369
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Moriyama Y; Ogawa H; Oshima S; Arai H; Takazoe K; Shimomura H; Hirai N; Suefuji H; Soejima H; Nishiyama K; Misumi K; Yasue H
Coron Artery Dis; 1998; 9(10):691-6. PubMed ID: 9894621
[TBL] [Abstract][Full Text] [Related]
19. Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Muth H; Maus U; Wygrecka M; Lohmeyer J; Grimminger F; Seeger W; Günther A
Crit Care Med; 2004 Jan; 32(1):217-26. PubMed ID: 14707582
[TBL] [Abstract][Full Text] [Related]
20. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor.
Gómez C; Páramo JA; Colucci M; Rocha E
Thromb Haemost; 1989 Sep; 62(2):694-8. PubMed ID: 2683190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
